此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effect of Interval Cancer and Screening Process on Survival and Disease-free Period in Breast Cancer

2017年5月22日 更新者:Maria Sala、Parc de Salut Mar

CAMISS Retrospective Cohort - Effect of Interval Cancer and Screening Process on Survival and Disease-free Period in Breast Cancer

This is a multicenter retrospective cohort of women participating in breast cancer screening programs in Spain between 2000 and 2009, with a cancer diagnosed during the screening or between the screening interval (interval cancer), specifically true interval cancers and false negatives. The investigators obtained woman-related information (including breast density), tumor-related information (including tumor phenotype), and follow-up information (including relapses, second neoplasms and vital status at the end of follow up (June 2014)). The objective is to evaluate the survival and disease-free period of women participating in screening programs for breast cancer with a cancer diagnosed during the screening or an interval cancer, specifically true interval cancers and false negatives.

This study is part of a broader project (CAMISS study), which also includes one prospective cohort (CAMISS Prospective cohort - Identifier in ClinicalTrials.gov: NCT02439554).

研究概览

详细说明

The general objective for this study is to evaluate the survival and disease-free period of women participating in screening programs for breast cancer with a cancer diagnosed during the screening or an interval cancer, specifically true interval cancers and false negatives.

The cohort has information of women participating in breast cancer screening programs in Spain between 2000 and 2009, with a breast cancer diagnosed during the screening or between the screening interval (interval cancer), specifically true interval cancers and false negatives. The investigators obtained woman-related information (including breast density), tumor-related information (including tumor phenotype), and follow-up information (including relapses, second neoplasms and vital status at the end of follow up (June 2014)).

Expected results: Nowadays there are no results of cohort analysis of the diagnostic process of care that integrates all those different aspects. This study will complement the evaluation of population screening, specifically the interval cancer and the impact on survival and disease-free period taking into account relevant variables like breast density, tumor phenotype, clinical complications, readmissions, and the surgical approach.

This study is part of a broader project (CAMISS study) coordinated by the Evaluation of Health Services of Epidemiology and Public Health Group, which consists of two cohorts of women diagnosed with breast cancer: a prospective cohort (n=2,040 incident cases of breast cancer diagnosed in 18 hospitals of 5 Spanish regions) (Identifier in ClinicalTrials.gov: NCT02439554) and a retrospective cohort of screened women diagnosed with breast cancer between 2000 and 2009 in two Spanish regions (n=1,086).

The general objective of the CAMISS study is to evaluate different aspects of health care received by patients with breast cancer like the diagnostic process, treatment, complications, survival, costs and quality of life to provide information to improve the effectiveness and cost-effectiveness of interventions, reduce variability, have better predictive rules and increase the quality of life.

研究类型

观察性的

注册 (实际的)

1086

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 至 69年 (成人、年长者)

接受健康志愿者

有资格学习的性别

女性

取样方法

非概率样本

研究人群

Women screened for breast cancer and diagnosed for breast cancer in the screening program (screen-detected cancer) or within the interval between 2 screening rounds (interval cancer)

描述

Inclusion Criteria:

  • Women aged between 50 to 69 years with invasive or in situ breast cancer.

Exclusion Criteria:

  • Women diagnosed with lobular carcinoma in situ.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:队列
  • 时间观点:追溯

队列和干预

团体/队列
干预/治疗
Screened women with breast cancer
Cancers detected as a result of screening mammograms.
Cancers diagnosed after a negative screening mammogram and before the next screening invitation (2 years in Spain)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Mortality
大体时间:From date of cancer diagnosis until the date of death from any cause, assessed up to 14 years
Death from any cause
From date of cancer diagnosis until the date of death from any cause, assessed up to 14 years

次要结果测量

结果测量
大体时间
Recurrences and second breast neoplasms
大体时间:From date of cancer diagnosis until the date of the first recurrence or second breast neoplasm, whichever came first, assessed up to 14 years
From date of cancer diagnosis until the date of the first recurrence or second breast neoplasm, whichever came first, assessed up to 14 years
Treatment-related complications
大体时间:From the date of surgery until the end of follow-up, assessed up to 14 years.
From the date of surgery until the end of follow-up, assessed up to 14 years.
Readmissions to hospital for reasons related to breast cancer
大体时间:From the date of surgery until the end of follow-up, assessed up to 14 years.
From the date of surgery until the end of follow-up, assessed up to 14 years.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2013年1月1日

初级完成 (实际的)

2014年6月30日

研究完成 (实际的)

2015年12月31日

研究注册日期

首次提交

2017年5月18日

首先提交符合 QC 标准的

2017年5月22日

首次发布 (实际的)

2017年5月24日

研究记录更新

最后更新发布 (实际的)

2017年5月24日

上次提交的符合 QC 标准的更新

2017年5月22日

最后验证

2017年5月1日

更多信息

与本研究相关的术语

其他研究编号

  • CAMISS study

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅